Citius Oncology(CTOR.US)

Last Updated 19:00:00 ET
longbridge loading

Citius Oncology | 8-K: FY2026 Q2 Revenue: USD 1.667 M

Earnings Watch·
US
CTOR
-3.15%
Earnings Watch·
US
CTOR
-3.15%

16:30 ETCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

prnewswire·
US
CTXR
+6.81%
US
PBE
-0.19%
US
BBH
-0.44%
prnewswire·
US
CTXR
+6.81%
US
PBE
-0.19%
US
BBH
-0.44%

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | CTOR Stock News

StockTitan·
US
CTOR
-3.15%
StockTitan·
US
CTOR
-3.15%

Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility

Tip Ranks·
US
CTXR
+6.81%
US
CTOR
-3.15%
US
LABU
-2.17%
Tip Ranks·
US
CTXR
+6.81%
US
CTOR
-3.15%
US
LABU
-2.17%

Citius raises $36.5m for Lymphir commercialisation

Pharmaceutical Technology·
US
CTXR
+6.81%
Pharmaceutical Technology·
US
CTXR
+6.81%

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization | CTOR Stock News

StockTitan·
US
CTOR
-3.15%
US
IHE
+0.03%
US
IBB
-0.46%
StockTitan·
US
CTOR
-3.15%
US
IHE
+0.03%
US
IBB
-0.46%
© 2026 Longbridge｜Disclaimer